A well-known pharmaceutical company announced to withdraw from the research and development of diabetes and cardiovascular drugs!

[pharmaceutical network industry news] on December 9, Paul Hudson, CEO of Sanofi, announced a new strategic framework and said it would lead Sanofi to the next cycle The new strategic framework includes four key priorities to drive innovation and growth, including focusing on targeted biopharmaceuticals dupixent and vaccines, and promoting research and development of innovative therapies Among them, it should be noted that the research and development of diabetes and cardiovascular drugs that have brought Sanofi market leading position in the past will be suspended, and the marketing plan of efpeglenatide, a diabetes drug, will not be continued It is reported that efpeglenatide is a long-acting GLP-1 receptor agonist jointly developed by South Korea, the United States and France Currently, it is in the third phase of clinical research Sanofi promises to complete the ongoing research, and then will find a partner to take over the subsequent commercialization work In fact, diabetes medicine has been a profitable business for Sanofi for many years, but in recent years, patients' dispute over the price of insulin, as well as the severe actions of insurance companies and pharmacy welfare managers, have seriously damaged the income of this life-saving medicine At the same time, several government surveys on the price of insulin are under way, which further increases the pressure on manufacturers In response to these pressures, Sanofi's competitors in the field of diabetes, Novo Nordisk and Lilly, have invested heavily in the research and development of new drugs But Sanofi's efforts in this area have failed, and the company is developing a new type of antidiabetic drug far behind its competitors Mr Hudson said Sanofi would no longer launch the product because it would take a lot of investment to catch up with competitors And the reason for giving up cardiovascular disease research is actually the same "It's not easy for a company like ours with an incredibly proud history to get out of cardiovascular disease and diabetes," Hudson told reporters Although it is a difficult choice, we are making such a choice " In the past, Sanofi was a big Mac in the field of cardiovascular and diabetes It has created the king of medicine, Plavix and Lantus Now it's amazing to quit the two common disease areas Coincidentally, Amgen, Sanofi's old friend, announced last month that he would withdraw from the research and development of another common public disease field, central disease, and then signed a $2.7 billion cooperation contract with Baiji to jointly develop tumor drugs Last year, Novartis announced that it would stop early research and development of antibiotics and antiviral drugs and cut 140 jobs Novartis said that although the scientific basis of these projects is solid, due to limited resources, Novartis decided to focus on areas that can better improve the health of patients It is worth noting that prior to Novartis' withdrawal, pharmaceutical giants such as AstraZeneca, Sanofi, aligen and Madison pharmaceutical have also given up antibiotic and antiviral research In fact, it is not a good thing for the pharmaceutical industry that many well-known pharmaceutical companies have withdrawn from the field of common diseases However, industry insiders say that there are three main reasons for forcing these traditional large pharmaceutical companies to go out of their comfort zone and give up the R & D, market and approval support system that they have worked hard for many years: first, the standard therapy is too strong, second, the technology is too complex, and third, the change of payment environment Generally speaking, the withdrawal of pharmaceutical enterprises is also a must.